OM — Outset Medical, Inc.

Summary of Outset Medical Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $119.5 million, a 5% increase from 2024, aligning with revised guidance.
• Product Revenue: $84.8 million, up 5% year-over-year; service and other revenue at $34.7 million, a 6% increase.
• Gross Margin: Non-GAAP gross margin reached 39.6% for the year, with Q4 gross margin at 42.9%, reflecting a 500 basis point improvement year-over-year.
• Operating Loss: Non-GAAP operating loss narrowed to $13.3 million in Q4, down from $15.5 million in Q4 2024; full-year net loss decreased by 31% to $65.4 million.
• Cash Position: Ended Q4 with $173 million in cash, with a cash burn of approximately $9 million for the quarter.

2. Strategic Updates and Business Highlights

• Next-Generation Tablo Platform: FDA clearance received for the next-gen Tablo, emphasizing cybersecurity and performance enhancements, expected to launch in Q2 2026.
• Customer Satisfaction: Maintained a CSAT score above 95%, reflecting strong customer service.
• Market Expansion: Tablo is now utilized in approximately 1,000 acute care sites; new agreements signed with major health systems.
• Cost Structure: Significant reduction in cash usage by $70 million in 2025, alongside investments in technology and leadership.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $125 million and $130 million, representing a 5% to 9% increase over 2025.
• Gross Margin Expectations: Anticipated to be in the low to mid-40% range, with improvements expected from reduced manufacturing under-absorption.
• Operating Expenses: Forecasted to grow at half the rate of revenue growth, aiming for continued operating leverage.
• Cash Usage: Expected to decrease in 2026 compared to the $46 million used in 2025, with Q1 anticipated to be the highest cash usage quarter.

4. Bad News, Challenges, or Points of Concern

• Product Revenue Decline: Q4 product revenue of $19.9 million was below the $21 million reported in the same quarter last year, attributed to order timing.
• Sales Cycle Length: Larger deals have longer sales cycles (9 to 12 months or more), which could impact revenue timing and predictability.
• Market Conditions: No significant changes in hospital capital budgets were reported, which could affect future sales growth.

5. Notable Q&A Insights

• Next-Gen Tablo Impact: The new platform is expected to attract interest from hospitals concerned about cybersecurity, potentially shortening sales cycles.
• Sales Force Stability: The sales organization remains stable post-leadership changes, with a search ongoing for a new sales leader.
• Pipeline Growth: The pipeline has grown consistently, with diversification across hospital sizes and types, including critical access hospitals.
• Gross Margin Projections: While the new Tablo may initially impact margins due to increased console sales, long-term benefits from product innovation are expected to enhance margins.

Overall, Outset Medical demonstrated resilience in 2025, with strategic advancements and a positive outlook for 2026, despite facing challenges in product revenue and longer sales cycles.